Advertisement

State of the science: Uterine sarcomas: From pathology to practice

Published:August 21, 2020DOI:https://doi.org/10.1016/j.ygyno.2020.08.008

      Highlights

      • Pre-operative evaluation can decrease risk of operating on an unsuspected malignancy; morcellation of a sarcoma should be avoided.
      • Adjuvant treatment of early stage leiomyosarcomas is controversial with no convincing evidence that adjuvant chemotherapy improves outcomes outcomes.
      • Multiple chemotherapy agents, radiotherapy, and hormonal agents have activity in recurrent leiomyosarcoma.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Keshavarz H.
        • Hillis S.
        • Kieke B.
        Hysterectomy Surveillance - United States.
        • Merrill R.M.
        Hysterectomy surveillance in the United States, 1997 through 2005.
        Med. Sci. Monit. 2008; 14: CR24-CR31
        • Wright J.D.
        • Ananth C.V.
        • Lewin S.N.
        • et al.
        Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease.
        JAMA. 2013; 309: 689-698https://doi.org/10.1001/jama.2013.186
        • Pritts E.A.
        • Parker W.H.
        • Brown J.
        • Olive D.L.
        Outcome of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review.
        J. Minim. Invasive Gynecol. 2015; 22: 26-33https://doi.org/10.1016/j.jmig.2014.08.781
        • Chan J.K.
        • Gardner A.B.
        • Thompson C.A.
        • Kapp D.S.
        The use of clinical characteristics to help prevent morcellation of leiomyosarcoma: an analysis of 491 cases.
        Am. J. Obstet. Gynecol. 2015; 213: 873-874https://doi.org/10.1016/j.ajog.2015.07.040
      1. Laparoscopic Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication - Use Discouraged Due to Increased Risk in Women with Uterine Fibroids. U.S. Food and Drug Administration Communication, Apr 17, 2014
        • AAGL Advancing Minimally Invasive Gynecology Worldwide
        AAGL practice report: Morcellation during uterine tissue extraction.
        J. Minim. Invasive Gynecol. 2014; 21: 517-530https://doi.org/10.1016/j.jmig.2014.05.010
      2. Society of Gynecologic Oncology SGO position statement: Morcellation.
        • Committee on Gynecologic Practice
        Committee opinion no 701: choosing the route of hysterectomy for benign disease.
        Obstet. Gynecol. 2017; 129: e155-e159https://doi.org/10.1097/AOG.0000000000002112
        • Wright J.D.
        • Tergas A.I.
        • Burke W.M.
        • et al.
        Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation.
        JAMA. 2014; 312: 1253-1255https://doi.org/10.1001/jama.2014.9005
        • Leibsohn S.
        • d’Ablaing G.
        • Mishell Jr., D.R.
        • Schlaerth J.B.
        Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.
        Am. J. Obstet. Gynecol. 1990; 162: 968-976https://doi.org/10.1016/0002-9378(90)91298-q
        • Goto A.
        • Takeuchi S.
        • Sugimura K.
        • Maruo T.
        Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus.
        Int. J. Gynecol. Cancer. 2002; 12: 354-361https://doi.org/10.1046/j.1525-1438.2002.01086.x
        • Yoshida Y.
        • Kiyono Y.
        • Tsujikawa T.
        • Kurokawa T.
        • Okazawa H.
        • Kotsuji F.
        Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
        Eur. J. Nucl. Med. Mol. Imaging. 2011; 38: 1824-1831https://doi.org/10.1007/s00259-011-1851-8
        • Park J.Y.
        • Park S.K.
        • Kim D.Y.
        • et al.
        The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
        Gynecol. Oncol. 2011; 122: 255-259https://doi.org/10.1016/j.ygyno.2011.04.021
        • George S.
        • Barysauskas C.
        • Serrano C.
        • et al.
        Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
        Cancer. 2014; 120: 3154-3158https://doi.org/10.1002/cncr.28844
        • Bogani G.
        • Cliby W.A.
        • Aletti G.D.
        Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis.
        Gynecol. Oncol. 2015; 137: 167-172https://doi.org/10.1016/j.ygyno.2014.11.011
        • Dotson S.
        • Landa A.
        • Ehrisman J.
        • Secord A.A.
        Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy.
        Gynecol. Oncol. Res. Pract. 2018; 5 (Published 2018 Oct 30): 8
        • Boruta D.M.
        • Shibley T.
        Power Morcellation of unsuspected high-grade leiomyosarcoma within an inflated containment bag: 2-year follow-up.
        J. Minim. Invasive Gynecol. 2016; 23: 1009-1011https://doi.org/10.1016/j.jmig.2016.06.017
        • Arias-Stella 3rd, J.A.
        • Benayed R.
        • Oliva E.
        • et al.
        Novel PLAG1 gene rearrangement distinguishes a subset of uterine myxoid leiomyosarcoma from other uterine myxoid mesenchymal tumors.
        Am. J. Surg. Pathol. 2019; 43: 382-388https://doi.org/10.1097/PAS.0000000000001196
        • Haimes J.D.
        • Stewart C.J.R.
        • Kudlow B.A.
        • et al.
        Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1.
        Am. J. Surg. Pathol. 2017; 41: 773-780https://doi.org/10.1097/PAS.0000000000000801
        • Kurman R.J.
        • Carcangiu M.L.
        • Herrington C.S.
        • et al.
        World Health Organization Classification of Tumours of Female Reproductive Organs.
        World Health Organization, Lyon, France2014
        • Lewis N.
        • Soslow R.A.
        • Delair D.F.
        • et al.
        ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity.
        Mod. Pathol. 2018; 31: 674-684https://doi.org/10.1038/modpathol.2017.162
        • Omura G.A.
        • Blessing J.A.
        • Major F.
        • et al.
        A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study.
        J. Clin. Oncol. 1985; 3: 1240-1245https://doi.org/10.1200/JCO.1985.3.9.1240
        • Reed N.S.
        • Mangioni C.
        • Malmström H.
        • et al.
        Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874) [published correction appears in Eur J Cancer. 2008 Jul; 44 (11): 1612].
        Eur. J. Cancer. 2008; 44: 808-818https://doi.org/10.1016/j.ejca.2008.01.019
        • Hensley M.L.
        • Blessing J.A.
        • Mannel R.
        • Rose P.G.
        Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a gynecologic oncology group phase II trial.
        Gynecol. Oncol. 2008; 109: 329-334https://doi.org/10.1016/j.ygyno.2008.03.010
        • Hensley M.L.
        • Maki R.
        • Venkatraman E.
        • et al.
        Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
        J. Clin. Oncol. 2002; 20: 2824-2831https://doi.org/10.1200/JCO.2002.11.050
        • Pervaiz N.
        • Colterjohn N.
        • Farrokhyar F.
        • Tozer R.
        • Figueredo A.
        • Ghert M.
        A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
        Cancer. 2008; 113: 573-581https://doi.org/10.1002/cncr.23592
        • Hensley M.L.
        • Wathen J.K.
        • Maki R.G.
        • et al.
        Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
        Cancer. 2013; 119: 1555-1561https://doi.org/10.1002/cncr.27942
        • Pautier P.
        • Floquet A.
        • Gladieff L.
        • et al.
        A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
        Ann. Oncol. 2013; 24: 1099-1104https://doi.org/10.1093/annonc/mds545
        • Ricci S.
        • Giuntoli 2nd, R.L.
        • Eisenhauer E.
        • et al.
        Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?.
        Gynecol. Oncol. 2013; 131: 629-633https://doi.org/10.1016/j.ygyno.2013.08.037
        • Seagle B.L.L.
        • Sobecki-Rausch J.
        • Strohl A.E.
        • Shilpi A.
        • Grace A.
        • Shahabi S.
        Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study.
        Gynecol. Oncol. 2017; 145: 61-70
        • Bogani G.
        • Fucà G.
        • Maltese G.
        • Ditto A.
        • Martinelli F.
        • Signorelli M.
        • et al.
        Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta-analysis.
        Gynecol. Oncol. 2016; 143: 443-447
        • Littell R.D.
        • Tucker L.Y.
        • Raine-Bennett T.
        • et al.
        Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: trends and survival outcomes.
        Gynecol. Oncol. 2017; 147: 11-17https://doi.org/10.1016/j.ygyno.2017.07.122
        • Hensley M.L.
        • Enserro D.
        • Hatcher H.
        • et al.
        Adjuvant gemcitabine plus Docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a phase III NRG Oncology/Gynecologic Oncology Group Study [published online ahead of print, 2018 Oct 5].
        J. Clin. Oncol. 2018; 36JCO1800454https://doi.org/10.1200/JCO.18.00454
        • Gillams A.
        • Goldberg N.
        • Ahmed M.
        • et al.
        Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013.
        Eur. Radiol. 2015; 25: 3438-3454https://doi.org/10.1007/s00330-015-3779-z
        • Shady W.
        • Petre E.N.
        • Gonen M.
        • et al.
        Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes–a 10-year experience at a single center.
        Radiology. 2016; 278: 601-611https://doi.org/10.1148/radiol.2015142489
        • Ruers T.
        • Van Coevorden F.
        • Punt C.J.
        • et al.
        Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial.
        J. Natl. Cancer Inst. 2017; 109https://doi.org/10.1093/jnci/djx015
        • Hirbe A.C.
        • Jennings J.
        • Saad N.
        • et al.
        A phase II study of tumor ablation in patients with metastatic sarcoma stable on chemotherapy.
        Oncologist. 2018; 23: 760-e76https://doi.org/10.1634/theoncologist.2017-0536
        • Pawlik T.M.
        • Vauthey J.N.
        • Abdalla E.K.
        • Pollock R.E.
        • Ellis L.M.
        • Curley S.A.
        Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver.
        Arch. Surg. 2006; 141: 537-544https://doi.org/10.1001/archsurg.141.6.537
        • NCCN
        Guidelines, at.
        • Benson C.
        • Miah A.B.
        Uterine sarcoma - current perspectives.
        Int. J. Women’s Health. 2017; 9 (Published 2017 Aug 31): 597-606
        • Takaki H.
        • Yamakado K.
        • Nakatsuka A.
        • et al.
        Frequency of and risk factors for complications after liver radiofrequency ablation under CT fluoroscopic guidance in 1500 sessions: single-center experience.
        AJR Am. J. Roentgenol. 2013; 200: 658-664https://doi.org/10.2214/AJR.12.8691
        • Hensley M.L.
        • Miller A.
        • O’Malley D.M.
        • et al.
        Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
        J. Clin. Oncol. 2015; 33: 1180-1185https://doi.org/10.1200/JCO.2014.58.3781
        • Maki R.G.
        • Wathen J.K.
        • Patel S.R.
        • et al.
        Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected] [published correction appears in J Clin Oncol. 2007 Aug 20; 25 (24):3790].
        J. Clin. Oncol. 2007; 25: 2755-2763https://doi.org/10.1200/JCO.2006.10.4117
        • Seddon B.
        • Strauss S.J.
        • Whelan J.
        • et al.
        Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
        Lancet Oncol. 2017; 18: 1397-1410https://doi.org/10.1016/S1470-2045(17)30622-8
        • Hensley M.L.
        • Patel S.R.
        • von Mehren M.
        • et al.
        Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: subgroup analysis of a phase 3, randomized clinical trial.
        Gynecol. Oncol. 2017; 146: 531-537https://doi.org/10.1016/j.ygyno.2017.06.018
        • Tap W.D.
        • Wagner A.J.
        • Schöffski P.
        • et al.
        Effect of doxorubicin plus Olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial.
        JAMA. 2020; 323: 1266-1276https://doi.org/10.1001/jama.2020.1707
        • Kapp D.S.
        • Shin J.Y.
        • Chan J.K.
        Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy.
        Cancer. 2008; 112: 820-830https://doi.org/10.1002/cncr.23245
        • Nasioudis D.
        • Chapman-Davis E.
        • Frey M.
        • Holcomb K.
        Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma.
        J. Gynecol. Oncol. 2017; 28e46https://doi.org/10.3802/jgo.2017.28.e46
        • Şahin H.
        • Karatas F.
        • Coban G.
        • et al.
        Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes.
        J. Gynecol. Oncol. 2019; 30e54https://doi.org/10.3802/jgo.2019.30.e54
        • Tanner E.J.
        • Toussaint T.
        • Leitao Jr., M.M.
        • et al.
        Management of uterine adenosarcomas with and without sarcomatous overgrowth.
        Gynecol. Oncol. 2013; 129: 140-144https://doi.org/10.1016/j.ygyno.2012.12.036
        • Nasioudis D.
        • Chapman-Davis E.
        • Frey M.
        • Holcomb K.
        Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma.
        J. Gynecol. Oncol. 2017; 28e46https://doi.org/10.3802/jgo.2017.28.e46
        • Renzulli P.
        • Weimann R.
        • Barras J.P.
        • Carrel T.P.
        • Candinas D.
        Low-grade endometrial stromal sarcoma with inferior vena cava tumor thrombus and intracardiac extension: radical resection may improve recurrence free survival.
        Surg. Oncol. 2009; 18: 57-64https://doi.org/10.1016/j.suronc.2008.07.003
        • Yoon A.
        • Park J.Y.
        • Park J.Y.
        • et al.
        Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases.
        Gynecol. Oncol. 2014; 132: 70-75https://doi.org/10.1016/j.ygyno.2013.10.029
        • Ip P.P.
        • Tse K.Y.
        • Tam K.F.
        Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
        Adv. Anat. Pathol. 2010; 17: 91-112https://doi.org/10.1097/PAP.0b013e3181cfb901
        • Guntupalli S.R.
        • Ramirez P.T.
        • Anderson M.L.
        • Milam M.R.
        • Bodurka D.C.
        • Malpica A.
        Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis.
        Gynecol. Oncol. 2009; 113: 324-326https://doi.org/10.1016/j.ygyno.2009.02.020
        • Cheng X.
        • Yang G.
        • Schmeler K.M.
        • et al.
        Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy.
        Gynecol. Oncol. 2011; 121: 323-327https://doi.org/10.1016/j.ygyno.2010.12.360
        • Zang Y.
        • Dong M.
        • Zhang K.
        • et al.
        Hormonal therapy in uterine sarcomas.
        Cancer Med. 2019; 8: 1339-1349https://doi.org/10.1002/cam4.2044
        • Berchuck A.
        • Rubin S.C.
        • Hoskins W.J.
        • Saigo P.E.
        • Pierce V.K.
        • Lewis Jr., J.L.
        Treatment of endometrial stromal tumors.
        Gynecol. Oncol. 1990; 36: 60-65https://doi.org/10.1016/0090-8258(90)90109-x
        • Harter P.
        • Sehouli J.
        • Reuss A.
        • et al.
        Phase II study evaluating PegLiposomal doxorubicin and carboplatin combination chemotherapy in gynecologic sarcomas and mixed epithelial-Mesenchymal tumors a phase II protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie study group (AGO-GYN 7).
        Int. J. Gynecol. Cancer. 2016; 26: 1636-1641https://doi.org/10.1097/IGC.0000000000000831